A day with

ADHD doesn’t
end early.

Consider a treatment that lasts
up to 16 hours post dose

measured from 2 or 4 hours.1

MYDAYIS® is the first and only mixed amphetamine salts (MAS) formulation that may help with improved attention up to 16 hours post-dose (measured from 2 or 4 hours) with once-daily dosing.1

Primary Endpoint1: Significant improvements in attention based on LS mean PERMP total scores up to 16 h post-dose. In Study 2, patients treated with Mydayis 50 mg had higher scores at 2 h and up to 16 h post-dose. In Study 3, patients on Mydayis 25 mg had higher scores at 4 h and up to 16 h post-dose.

Why Mydayis

TRIPLE-BEAD DELIVERY

for prolonged release

For over 20 years, Shire has been committed to ADHD research to help meet the needs of patients. Mydayis is the first ADHD treatment to use triple-bead delivery for extended release of MAS medication through the morning, afternoon, and evening.1

First Bead: Immediate-release immediate release in the stomach

First Bead:
Immediate-release
Immediate release in the stomach

Second Bead: Delayed-release (DR-1) Release at pH 5.5

Second Bead:
Delayed-release (DR-1)
Release at pH 5.5

Third Bead: Delayed-release (DR-2) Release at pH 7.0

Third Bead:
Delayed-release (DR-2)
Release at pH 7.0

Beads shown are not actual size or color.

Three types of beads in a single capsule release at different pH levels for prolonged amphetamine delivery.1

See how it works

Improved attention

Up to 16 hours

post-dose (measured from 2 or 4 hours)
vs placebo based on PERMP

IMPORTANT SAFETY INFORMATION (continued)

Contraindications

  • Known hypersensitivity to amphetamines or other ingredients of Mydayis. Angioedema and anaphylactic reactions have been reported with other amphetamines.
  • Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of last MAOI dose, due to increased risk of hypertensive crisis.

In a prespecified supplementary analysis in Study 2, patients receiving Mydayis 50 mg demonstrated significant improvement in attention vs placebo on PERMP total score measured from 2 to 16 hours post-dose. The post-dose average score over all testing sessions was 285 for Mydayis and 262 for placebo (P <0.0001).1,2

Patients receiving Mydayis demonstrated significant improvement in attention vs placebo, measured from 2 to 16 hours post-dose

Efficacy with Mydayis was the primary endpoint in 2 phase II randomized, double-blind, placebo-controlled studies. Attention in ADHD was measured by the PERMP administered before dosing and at intervals up to 16 hours after dosing. PERMP is a skill-adjusted math test that is scored as the sum of math problems attempted and problems answered correctly.1-3

Another Duration of Effect Study
In the separate Study 3, adult patients who took Mydayis 25 mg experienced significantly greater improvement in attention from hours 4-16 post-dose compared with placebo on PERMP total score. The post-dose average score over all testing sessions was 268 for Mydayis and 249 for placebo (P <0.0001).1,3

Patients can

SAVE NOW*

We’ve made it simple for your patients to save on their prescription cost with our long-lasting savings program.

*Eligibility and restrictions apply.

Prescription savings card for ADHD treatment
References
  1. Mydayis [package insert]. Lexington, MA; Shire US Inc.
  2. Data on file; SPD465-201; Shire US Inc.
  3. Data on file; SPD465-203; Shire US Inc.